Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for ConvaTec Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $11.82.
Current Consensus is
Strong Buy
The current consensus among 3 polled investment analysts is to buy (strong buy) stock in ConvaTec Group. This rating has held steady since July 2024, when it changed from a Buy consensus rating.
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other causes, as well as critical care devices and products used in intensive care units and hospital settings. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for pumps used in continuous subcutaneous infusion treatments for conditions such as parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Read More